Hypercoagulable state in Cushing's syndrome: a systematic review - PubMed (original) (raw)
Review
. 2009 Aug;94(8):2743-50.
doi: 10.1210/jc.2009-0290. Epub 2009 May 19.
Affiliations
- PMID: 19454584
- DOI: 10.1210/jc.2009-0290
Review
Hypercoagulable state in Cushing's syndrome: a systematic review
Bregje Van Zaane et al. J Clin Endocrinol Metab. 2009 Aug.
Abstract
Context: It has been debated whether an increased risk of venous thromboembolism (VTE) exists in patients with Cushing's syndrome.
Objective: We aimed to summarize published literature on the effects of endogenous hypercortisolism on coagulation and fibrinolysis, as well as on the clinical outcome of VTE.
Data sources: We searched the MEDLINE and EMBASE databases up to July 2008. Review of reference lists further identified candidate studies.
Study selection: Two investigators independently performed study selection and data extraction. Eligible studies had to include Cushing's syndrome patients and either evaluate hemostatic parameters in comparison with control persons or posttreatment levels or describe the occurrence of VTE.
Data extraction: The Newcastle-Ottawa Scale was used to assess study quality. A scoring system divided studies into categories of low, medium and high quality.
Data synthesis: Of 441 identified publications, 15 reports were included. They contained information on eight cross-sectionals, two intervention, and eight cohort studies. No high-quality studies were identified. Hypercoagulability was suggested by high levels of factor VIII, factor IX, and von Willebrand factor and by evidence of enhanced thrombin generation. A risk of 1.9 and 2.5% was reported for VTE not provoked by surgery, whereas risk of postoperative VTE varied between 0 and 5.6%, with one outlier of 20%. VTE was reported as the cause of death in 0-1.9% of Cushing's syndrome patients.
Conclusions: Available studies suggest a high risk of venous thrombosis in patients with Cushing's syndrome. Glucocorticoid-induced hypercoagulability as well as surgery and obesity almost certainly contribute to this thrombotic tendency.
Similar articles
- Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: results from a prospective study before and after surgery.
Manetti L, Bogazzi F, Giovannetti C, Raffaelli V, Genovesi M, Pellegrini G, Ruocco L, Iannelli A, Martino E. Manetti L, et al. Eur J Endocrinol. 2010 Nov;163(5):783-91. doi: 10.1530/EJE-10-0583. Epub 2010 Aug 9. Eur J Endocrinol. 2010. PMID: 20696792 - Hypercoagulability in Cushing's syndrome: incidence, pathogenesis and need for thromboprophylaxis protocols.
Feelders RA, Nieman LK. Feelders RA, et al. Pituitary. 2022 Oct;25(5):746-749. doi: 10.1007/s11102-022-01261-9. Epub 2022 Jul 26. Pituitary. 2022. PMID: 35881275 Free PMC article. Review. - The thrombotic risk in Cushing's syndrome-questions, answers, and the algorithm to consider in its assessment: part I-thrombotic risk not related to surgery.
Bryk-Wiązania AH, Minasyan M, Świątkowska-Stodulska R, Undas A, Hubalewska-Dydejczyk A, Webb SM, Valassi E, Gilis-Januszewska A. Bryk-Wiązania AH, et al. Front Endocrinol (Lausanne). 2024 Mar 11;15:1350010. doi: 10.3389/fendo.2024.1350010. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38529392 Free PMC article. Review. - Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers.
Kastelan D, Dusek T, Kraljevic I, Polasek O, Giljevic Z, Solak M, Salek SZ, Jelcic J, Aganovic I, Korsic M. Kastelan D, et al. Endocrine. 2009 Aug;36(1):70-4. doi: 10.1007/s12020-009-9186-y. Epub 2009 Apr 21. Endocrine. 2009. PMID: 19381886 - Adverse effects of glucocorticoids: coagulopathy.
Coelho MC, Santos CV, Vieira Neto L, Gadelha MR. Coelho MC, et al. Eur J Endocrinol. 2015 Oct;173(4):M11-21. doi: 10.1530/EJE-15-0198. Epub 2015 May 13. Eur J Endocrinol. 2015. PMID: 25971647 Review.
Cited by
- [Comparison of coagulation function between adrenocorticotropic hormone independent Cushing syndrome and nonfunctional adrenal adenoma and its influence factors].
Wang W, Wang JN, Yu W, Zhu SN, Gao Y, Zhang JQ. Wang W, et al. Beijing Da Xue Xue Bao Yi Xue Ban. 2023 Dec 18;55(6):1062-1067. doi: 10.19723/j.issn.1671-167X.2023.06.017. Beijing Da Xue Xue Bao Yi Xue Ban. 2023. PMID: 38101790 Free PMC article. Chinese. - The risks of overlooking the diagnosis of secreting pituitary adenomas.
Brue T, Castinetti F. Brue T, et al. Orphanet J Rare Dis. 2016 Oct 6;11(1):135. doi: 10.1186/s13023-016-0516-x. Orphanet J Rare Dis. 2016. PMID: 27716353 Free PMC article. Review. - Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing's disease.
Guarnotta V, Ciresi A, Pitrone M, Pizzolanti G, Giordano C. Guarnotta V, et al. Endocrine. 2018 Feb;59(2):454-457. doi: 10.1007/s12020-017-1276-7. Epub 2017 Mar 17. Endocrine. 2018. PMID: 28303515 No abstract available. - Methylprednisolone, venous thromboembolism, and association with heparin to 30 days in hospital survival in severe Covid-19 pneumonia.
Go RC, Nyirenda T, Bojarian M, Hosseini DK, Rahim M, Kim K, Rose KM. Go RC, et al. BMC Pulm Med. 2022 Jan 6;22(1):6. doi: 10.1186/s12890-021-01810-1. BMC Pulm Med. 2022. PMID: 34986821 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical